Autolus Lifts 2026 AUCATZYL Sales Outlook

The Tip Desk · November 12, 2026 · 3 min read

Third-quarter net product revenue was $41.2 million, up 95% from a year earlier, as the company now expects full-year sales at or above $150 million.

Autolus Therapeutics plc (AUTL), a commercial-stage biopharmaceutical company developing programmed T cell therapies, reported AUCATZYL net product revenue of $41.2 million for the three months ended September 30, 2026, up 95% from $21.1 million a year earlier. The sequential step-down from $45.7 million in the second quarter, when year-over-year growth was 119%, marked a slower pace of expansion in the CD19 CAR T launch.

The company now expects full-year 2026 AUCATZYL net product revenue to be at or exceeding the upper end of $150 million, from prior guidance of $140 million to $150 million. Chief Executive Officer Dr. Christian Itin said the quarter’s sales were primarily driven by growth within existing authorized treatment centers as physicians gained experience with the therapy, supported by real-world data from the ROCCA consortium. Autolus attributed net revenues to increasing product demand both within existing centers and expansion into new centers, supplemented by contribution from UK sales.

Gross margin rose to 57% in the third quarter from 55% in the second quarter, versus a negative gross margin in the same period in 2025. Cost of sales decreased to $17.9 million from $28.6 million a year earlier. The company said the year-over-year improvement was primarily driven by a reduction in manufacturing cost per batch from increased volumes and operational efficiency initiatives, and lower inventory reserves and write-offs. Itin said the company continued to improve gross margin with execution on those manufacturing efficiency initiatives.

Loss from operations narrowed to $43.5 million from $71.6 million a year earlier. Net loss was $55.1 million, or $(0.21) a share, compared with $79.1 million, or $(0.30) a share, in the year-ago quarter. Research and development expenses increased to $30.9 million from $27.9 million, which the company said was primarily due to higher clinical manufacturing supply costs from clinical development, partially offset by lower salaries and other employment-related costs. Selling, general and administrative expenses decreased to $35.9 million from $36.3 million, which the company said was primarily due to salaries, other employment-related costs and professional fees supporting commercialization in the US and UK.

Cash, cash equivalents and marketable securities totaled $248.4 million at September 30, 2026, up from $201.6 million at June 30, 2026. The company said the increase was primarily driven by net cash inflows from the Perceptive Advisors senior secured note facility. Based on current operating plans, including anticipated AUCATZYL net revenues and proceeds of the combined first and second tranches totaling $100 million from that credit facility, Autolus expects cash to fund operations into the second quarter of 2028.

On September 9, 2026, the FDA granted regenerative medicine advanced therapy designation to obe-cel for systemic lupus erythematosus and lupus nephritis. Updated CARLYSLE data in severe refractory SLE, including up to 25 months of follow-up in adults, were scheduled to be presented as a poster at the American College of Rheumatology meeting on November 10. LUMINA, the pivotal Phase 2 study in refractory lupus nephritis, continues enrolling in five countries, with data expected in 2028. The Phase 2 portion of CATULUS in pediatric relapsed or refractory B-cell precursor ALL is on track, with data expected at the end of 2027.

After key-opinion-leader feedback at ACTRIMS/ECTRIMS that initial activity and biomarker data in progressive multiple sclerosis will require longer follow-up, Autolus plans to move the first data presentation to ECTRIMS Global in October 2027, when it expects 12 months or more of follow-up for the initial 12 patients dosed and data in up to 24 patients total. The Phase 1 ALARIC trial of AUTO8 in light-chain amyloidosis is ongoing, with initial data expected at ASH in December 2026.